Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease

Baisen Zhong, Weiyu Peng, Shan Du, Bingyi Chen, Yajuan Feng, Xinfeng Hu, Qi Lai, Shujie Liu, Zhong‐Wei Zhou, Pengfei Fang,

Small Science · 2022 · 27 citations · 0 references

DOIFull text

Open access

Concepts

Abstract

Oridonin Inhibits SARS-CoV-2 Oridonin, a natural product extracted from Rabdosia rubescens, possesses a wide range of pharmacological properties, including anti-inflammatory, anti-cancer, anti-microbial, neuroprotection, immunoregulation, etc. In article number 2100124, Baisen Zhong, Litao Sun, and co-workers demonstrate that Oridonin targets the SARS-CoV-2 3CL protease by covalently binding to cysteine145 in its active pocket to exert an anti-SARS-CoV-2 effect, which provides a novel candidate for the treatment of COVID-19.